A licensed 503A pharmacy may compound BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 for a named patient under HHS's conditions 12.
Non-enforcement, not approval: the policy is a non-binding draft and does not change state law 3.
Each peptide is limited to set forms, one peptide per product; blends and research-use-only vials are outside it 4.
On this page
- Where things stand
- The six peptides, their covered forms and who has announced them
- The ten conditions, in plain language
- Named licensed pharmacies
- Timeline
- What to watch
- Frequently asked questions
- Related on Grey Peptides
- Sources
Where things stand
Status checked November 18, 2026. The HHS policy is a draft, non-binding promise not to enforce, open to change; none of the six is FDA-approved or on the 503A bulks list. We re-read the policy and every pharmacy announcement on this page at source at least every 60 days.
On October 30, 2026 HHS published a notice saying it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician
compounding a drug from six peptides when every condition of its policy is met 1. The six are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 2. The notice calls the policy a draft; it is not binding on HHS or the public
, and HHS may revisit it if a safety signal or quality problem arises 1. It lasts until FDA decides in a final rule whether each peptide goes on the 503A bulks list 4.
This is conditional federal non-enforcement, not FDA approval
, and it does not change state law 3. Nothing in it covers vials sold as 'research use only' (our fact check).
The six peptides, their covered forms and who has announced them
| Peptide | Form named in Appendix B | Covered routes (Appendix B's words) | Licensed pharmacies announced | Encyclopedia |
|---|---|---|---|---|
| BPC-157 | BPC-157 acetate | subcutaneous, intramuscular, oral, and topical dosage forms | Olympia Pharmaceuticals | Entry |
| TB-500 | TB-500 acetate (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH) | subcutaneous or intramuscular injectable dosage forms | Olympia Pharmaceuticals | Entry |
| KPV | KPV acetate | topical and oral dosage forms | Olympia Pharmaceuticals | Entry |
| MOTS-c | MOTS-c acetate | subcutaneous or intramuscular injectable dosage forms | Olympia Pharmaceuticals | Entry |
| Semax | semax free base | intranasal use | Olympia Pharmaceuticals | Entry |
| Epitalon | epitalon acetate | subcutaneous or intramuscular injectable dosage forms that are dispensed in intermittent courses | Olympia Pharmaceuticals | Entry |
Routes from Appendix B 2; announcements from each pharmacy's own release 5. Each peptide's page lists what is not covered.
The ten conditions, in plain language
HHS holds back only when all ten are present 4:
- On the list. The peptide is one of the six in Appendix A.
- The right molecule, by the right route. It has the identity (sequence, structure, molecular weight and formula) and stays within the routes of administration that Appendix B sets for it.
- Tested raw material. The bulk peptide comes with a valid certificate of analysis covering identity, purity, potency and contaminants such as endotoxin and heavy metals, from an FDA-registered facility.
- A registered maker. The original manufacturer, "not a subsequent packer, repacker, labeler, or distributor", is registered with FDA and follows current good manufacturing practice.
- Reporting. The compounder reports what it makes, serious adverse events and product-quality problems to FDA's MedWatch and to the states involved.
- The label. The label says: "This is a compounded drug product. Not for resale."
- One peptide only. The product "contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A", so blends of two peptides are outside the policy.
- Oral forms must be shown to work. For a tablet, capsule or other oral form, the compounder keeps documentation that the formulation is adequately absorbed in people.
- Syringes only. "The only drug delivery device co-packaged or containing the compounded drug is an FDA 510(k)-cleared syringe."
- Everything else in the law. The product meets every other requirement of the Food, Drug, and Cosmetic Act, including a prescription for a named patient and sanitary compounding conditions.
Physicians who compound in their own offices must meet the same supplier, testing and reporting conditions as pharmacies, and state law still decides whether they may 3.
Named licensed pharmacies
| Pharmacy | Type | Licensed in | Announced | What it said |
|---|---|---|---|---|
| Olympia Pharmaceuticals | 503A pharmacy (the company also runs an FDA-registered 503B outsourcing facility) | "Olympia holds active licenses in 49 states" (its own release; the release does not say which state is missing). | November 12, 2026 5 | "Olympia plans to initially launch compounding for BPC-157 for patients with a valid prescription." It "plans to evaluate and roll out additional authorized peptides", "including KPV, TB-500, MOTS-c, semax, and epitalon", and "plans to make the peptides covered by the policy available to patients by December." |
We name a pharmacy here only if it is state-licensed and has itself announced compounding one of the six under the policy, and we link its own announcement. Naming one is not a recommendation: we have not inspected any pharmacy, tested its products or compared prices. Telehealth companies have also said they will offer some of these peptides; we name one only when its own announcement names the licensed pharmacy that fills its prescriptions, and none we read as of November 18, 2026 did. Check any pharmacy's license with your state board of pharmacy.
Timeline
- July 23, 2026. FDA's Pharmacy Compounding Advisory Committee votes on seven peptides over two days and recommends six of them for the 503A bulks list, against FDA staff's proposal; the vote is advice, not a rule. 6
- October 28, 2026. HHS releases its interim enforcement-discretion policy for the six. 3
- October 30, 2026. The notice of availability is published in the Federal Register, calling the policy a draft and opening two weeks for written comments. 1
- November 10, 2026. The Federation of State Medical Boards publishes an FAQ for state boards and physicians. 3
- November 12, 2026. Olympia Pharmaceuticals, a licensed 503A pharmacy, announces it will compound BPC-157 first, then evaluate the other five. 5
- November 13, 2026. Written comments on the policy close. 3
What to watch
- Whether HHS revises the policy after the comment period that closed November 13 3.
- Whether FDA proposes a rule adding any of the six to the 503A bulks list, which would replace the interim policy 4.
- Further pharmacy announcements and actual availability: the first named pharmacy planned to have BPC-157 for patients by December 5.
- State boards: several warned about research-grade peptides before the policy, and the policy leaves their authority intact 3.
Frequently asked questions
Are BPC-157 and the other five peptides legal now?
They are not FDA-approved. HHS says it will not act against licensed pharmacies and physicians that compound them for a named patient under ten conditions; the policy is a non-binding draft.13
Does the policy make research-use-only peptides legal?
No. It covers compounding by state-licensed pharmacies, federal facilities and licensed physicians that meet its conditions, not products sold outside a pharmacy.1
Can a 503B outsourcing facility make them?
The policy is written for 503A compounding; lawyers reading it say it does not cover 503B outsourcing facilities.7
Why do you name pharmacies when the rest of the site names no seller?
Because a licensed pharmacy filling a prescription under federal policy is the legal route this section exists to explain. We name only state-licensed pharmacies that announced it themselves, with their release, and we do not rank or recommend them.5
Related on Grey Peptides
Sources
Primary documents (the Federal Register notice, the HHS policy and appendices, the FSMB FAQ, FDA's meeting page), the pharmacy's own release and one law-firm analysis, all read November 18, 2026. Not legal or medical advice.
- Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Office of the Secretary, HHS. Notice of availability, 91 FR 68526-68527, October 30, 2026; docket HHS-OASH-2026-0496; FR Doc. 2026-22192. Read in full November 18, 2026. Source
- HHS: the policy with Appendix A (the six peptides) and Appendix B (identity and routes of administration), PDF. Read November 18, 2026. Source
- Federation of State Medical Boards: FAQs on the HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, November 10, 2026 (hosted by the Alabama Board of Medical Examiners). Read November 18, 2026. Source
- HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy text, undated PDF). Read November 18, 2026. Source
- Olympia Pharmaceuticals: Olympia Pharmaceuticals to compound select peptides under HHS interim enforcement policy. Company press release, GlobeNewswire, Orlando, Florida, November 12, 2026. The company's own statement. Read November 18, 2026. Source
- FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee, meeting page with FDA's briefing document for each peptide. Our compound-by-compound summary is on the PCAC hub. Source
- Arnold & Porter (law firm): HHS announces draft enforcement discretion policy paving way for pharmacies, client advisory, November 2026. Legal analysis, not the policy itself. Read November 18, 2026. Source
This page explains a federal enforcement policy; it is not legal or medical advice. The policy is non-binding and can change, and none of these peptides is FDA-approved. Naming a pharmacy is not a recommendation. Grey Peptides sells nothing and takes no payment from pharmacies.